Frederic Bouder
Cited by
Cited by
The changing nature of communication and regulation of risk in Europe
R Lofstedt, F Bouder, J Wardman, S Chakraborty
Journal of Risk Research 14 (4), 409-429, 2011
The tolerability of Risk
F Bouder, D Slavin, R Löfstedt
A New Framework for Risk Management. London: Earthscan, 2007
The COVID-19 pandemic: how can risk science help?
T Aven, F Bouder
Journal of Risk Research 23 (7-8), 849-854, 2020
Transparency in Europe: a quantitative study
F Bouder, D Way, R Löfstedt, D Evensen
Risk Analysis 35 (7), 1210-1229, 2015
New transparency policies: risk communication’s doom?
RE Löfstedt, F Bouder
Effective risk communication, 99-116, 2013
Regulating impurities in pharmaceutical products: a tolerability of risk approach?
F Bouder
Expert Review of Clinical Pharmacology 1 (2), 241-250, 2008
Evidence-based uncertainty analysis: What should we now do in Europe? A view point
R Lofstedt, F Bouder
Journal of Risk Research 24 (5), 521-540, 2021
Varieties of risk regulation in Europe: coordination, complementarity and occupational safety in capitalist welfare states
H Rothstein, D Demeritt, R Paul, AL Beaussier, M Wesseling, M Howard, ...
Socio-Economic Review 17 (4), 993-1020, 2019
Medicines transparency at the European Medicines Agency (EMA) in the new information age: the perspectives of patients
D Way, F Bouder, R Löfstedt, D Evensen
Journal of Risk Research 19 (9), 1185-1215, 2016
Pharmaceutical benefit–risk communication tools: a review of the literature
D Way, H Blazsin, R Löfstedt, F Bouder
Drug safety 40 (1), 15-36, 2017
When ‘must’means ‘maybe’: varieties of risk regulation and the problem of trade-offs in Europe
H Rothstein, AL Beaussier, O Borraz, F Bouder, D Demeritt, M de Haan, ...
HowSAFE WP 1, 15, 2015
The future of risk communication and the role of the pharmaceutical industry
S Chakraborty, F Bouder
Current drug safety 8 (1), 4-10, 2013
A comparative analysis of risk perception related to human health issues
FE Bouder
Risk society and the culture of precaution, 167-183, 2006
Risk-based governance against national obstacles? Comparative dynamics of Europeanization in Dutch, French, and German flooding policies
R Paul, F Bouder, M Wesseling
Journal of Risk Research 19 (8), 1043-1062, 2016
Risk communication of vaccines: challenges in the post-trust environment
F Bouder
Current Drug Safety 10 (1), 9-15, 2015
Governance for sustainable development in Canada
F Bouder
Governance for Sustainable Development: Five OECD Case Studies, 2001
Transparency and the Food and Drug Administration—A quantitative study
R Lofstedt, F Bouder, S Chakraborty
Journal of health communication 18 (4), 391-396, 2013
Effects of public trust on behavioural intentions in the pharmaceutical sector: data from six European countries
D Balog-Way, D Evensen, R Löfstedt, F Bouder
Journal of Risk Research 24 (6), 645-672, 2021
Transparency of medicines data and safety issues–a European/US study of doctors’ opinions: what does the evidence show?
R Löfstedt, D Way, F Bouder, D Evensen
Journal of Risk Research 19 (9), 1172-1184, 2016
Benefit/risk communication by the European Medicines Agency: a study of influential stakeholders' expectations and attitudes
F Bouder
European Medicines Agency (EMA), 2011
The system can't perform the operation now. Try again later.
Articles 1–20